Jan 24, 2019 · Intracerebral bleed is the most known and feared complication after tPA administration. tPA-associated orolingual angioedema (TAOA) is a less common but potentially fatal complication of tPA. We report a patient who developed hemi …

A well-documented complication of administering tissue plasminogen activator (tPA) in stroke patients is acute intracranial bleeding. A lesser known but still significant complication is angioedema secondary to tPA administration, which can develop ...

Jun 11, 2019 · Oral angioedema (OA) is a rare but life-threatening complication in patients with ischemic stroke receiving intravenous thrombolysis with r-tPA (recombinant tissue-type plasminogen activator). This study intended to determine associations between thrombolysis-related OA and ischemic stroke lesion sites using a voxel-wise lesion analysis.

Apr 3, 2014 · tPA-associated angioedema is a rare (1.3 – 5.1% incidence), but known complication. One must remain vigilant and be on guard for this. While treating one potentially life-threatening disease, you may induce another.

Recombinant tissue plasminogen activator (rtPA), an enzyme that catalyzes the conversion of plasminogen to plasmin resulting in fibrinolysis, is used for the treatment of acute ischemic strokes. The use of this medication is not without complication. One …

Jan 15, 2025 · Orolingual angioedema is a recognized adverse effect of tissue plasminogen activator (tPA) treatment in the setting of acute ischemic stroke (AIS). Although its incidence is relatively low (0.1‐0.7%), the reaction is generally mild but may trigger life‐threatening airway occlusion and necessitate rapid intubation.

Jan 14, 2021 · Angioedema mediated by tPA is a rare and potentially life-threatening occurrence. At the first signs of tPA-induced angioedema, hospital staff should be aware of the commonly used interventions and medications.

Jun 28, 2024 · Angioedema without concomitant urticaria is a well-known complication of treatment with the recombinant tissue-type plasminogen activator (r-tPA) alteplase and its genetically modified variant tenecteplase. It is potentially lethal when causing airway obstruction and can require intubation.

Although cases of angioedema have been documented in patients not receiving angiotensin converting enzyme inhibitors (ACE-I), it appears patients receiving ACE-I may be at an increased risk of developing angioedema after tPA administration.

It is estimated that orolingual angioedema occurs in approximately 1.3% to 5% of patients with stroke receiving IV r-tPA. 13,62,63 It usually presents as a transient, self-limited swelling of the tongue and lips but can potentially cause airway obstruction and respiratory compromise requiring emergent intubation or cricothyrotomy. 13,64 The ...